Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tucatinib plus trastuzumab and pertuzumab maintenance for metastatic HER2-positive breast cancer
NL-OMON56309Phase 3Recruiting
- Sponsor
- Seagen Inc.
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Tucatinib + trastuzumab + pertuzumab with Placebo + trastuzumab + pertuzumab (2 arms). Primary endpoint: Progression-free survival by investigator. Started Nov 2023; status: recruiting.
02
Drugs
tucatinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON56309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56309.